Navigation Links
OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
Date:2/28/2011

BOTHELL, Wash., and VANCOUVER, British Columbia, Feb. 28, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI) announced today that Scott Cormack, OncoGenex's president and chief executive officer, will take part in a panel discussion on novel cancer treatments at the upcoming RBC Capital Markets Healthcare Conference. The panel discussion entitled, "Cancer Treatments: Under the Radar Unique Late-Stage Opportunities", will take place on Wednesday, March 2, 2011, at 9 a.m. (Eastern Time) in the Holmes I Room of the New York Palace Hotel, in New York City.

A live audio webcast of the panel discussion will be available on Investor Relations page of the OncoGenex website at www.oncogenex.com. A replay of the webcast will also be available on the Company's website for a period of 90 days.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceuticals have entered a global collaboration and license agreement to develop and commercialize OncoGenex's lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011. OGX-427 is in Phase 2 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
2. Isis Pharmaceuticals to Receive $10 Million From OncoGenex License of OGX-011 to Teva
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... , April 20, 2015  SillaJen, Inc., a ... of oncolytic immunotherapy products for cancer, today announced ... the Annual Meeting of the American Association for ... murine adapted version of its lead product candidate, ... is an oncolytic immunotherapy designed to 1) rapidly ...
(Date:4/20/2015)... , April 20, 2015 The preclinical contract research ... testing of drugs and safety testing of medical devices, announces ... at this week,s workshop " Drug Transporters in ADME: From ... MD . The title of Dr. Hidalgo,s talk is ... a session entitled "Transporter Tools of the Future." ...
(Date:4/20/2015)... , April 20, 2015   Gateway ... Research and Training Institute today expanded its Naloxone: ... outpatient locations.  A $50,000 grant from the ... research project possible.  The yearlong ... to patients and their family members upon completion ...
Breaking Medicine Technology:SillaJen Presents Data Demonstrating Pexa-Vec Synergy with Angiogenesis Inhibitors: A Collaboration with University of California, San Francisco 2SillaJen Presents Data Demonstrating Pexa-Vec Synergy with Angiogenesis Inhibitors: A Collaboration with University of California, San Francisco 3Absorption Systems Chief Scientist Ismael Hidalgo to Present at International Workshop on Drug Transporters 2Gateway Rehab and the Kenneth S. Ramsey, PhD Research and Training Institute expand Naloxone: Increasing Access, Saving Lives research project to outpatient locations 2Gateway Rehab and the Kenneth S. Ramsey, PhD Research and Training Institute expand Naloxone: Increasing Access, Saving Lives research project to outpatient locations 3
... Calif., Dec. 4 Vermillion, Inc. (VRML) (Pink Sheets: VRMLQ) ... Amended Plan of Reorganization and related amended Disclosure Statement with ... , A hearing to consider the adequacy of ... with the hearing on the confirmation of the Plan scheduled ...
... , EMERYVILLE, Calif., Dec. 4 ... it will host an investor teleconference and webcast. Principal ... and/or refractory multiple myeloma, as featured at the 51st American ... begin at 9:00 a.m. CT/10:00 a.m. ET on Monday, December ...
Cached Medicine Technology:Vermillion Files Amended Plan of Reorganization and Exchanges Debt 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 3Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2
(Date:4/20/2015)... Bronx, NY (PRWEB) April 20, 2015 The ... are introducing the community to Bella Diosa Laser Med Spa ... invited to a spa party on from 12–7 p.m. on ... The event will include drinks and refreshments. Participants will also ... Attendees will receive a free gift with any purchase, as ...
(Date:4/20/2015)... is a seemingly idyllic and tranquil island oasis in ... off the southeastern coast of Africa, the tiny nation ... everyone lives together in harmony. , But the shimmering ... drug abuse. In fact, it carries a dubious designation: ... in eastern Africa. , “Many youngsters, they know the ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 At the ... held the “RockNRolla Movie Awards” EcoLuxe Lounge, with Choices ... Angeles’ leading producer of sustainable product placement in TV ... of socially conscious and ecologically sound goods and services ... star Chase Masterson hosted the Choices Celebrity Interview Lounge, ...
(Date:4/20/2015)... Connecticut (PRWEB) April 20, 2015 ... Moreen Donahue, DNP, RN, NEA-BC, FAAN who was ... Nursing Education and Research in September 2014, is ... Nursing Officer to lead the development of Western ... this newly created role, Donahue will be responsible ...
(Date:4/20/2015)... 2015 The normal response from the doctor ... we could do.” Especially if the patient sought medical care ... should be much different. So it’s critical the patient’s loved ... be done?” , Not every emergency room physician or ... can be done.” But, according to Ronald P. Benitez ...
Breaking Medicine News(10 mins):Health News:Bella Diosa Says Hello to Yonkers Community with Spa Party 2Health News:Voice For Humanity: Choolun Bhojoo leads the fight to rid Mauritius of a drug plague 2Health News:Choices Recovery South Bend Talks About Healthy Decisions with TV's Adrienne Janic 2Health News:Nursing Executive to Develop and Lead Nursing Leadership Program at Western Connecticut Health Network 2Health News:"What More Can Be Done?” – The Critical Question That Can Save a Stroke Victim 2Health News:"What More Can Be Done?” – The Critical Question That Can Save a Stroke Victim 3
... ... wellness. Learn how to improve the look and strength of your abdominal muscles and improve ... on this new Web site. , ... June 17, 2010 -- A new Web site has been developed to help anyone get in ...
... ... to Bring Fresh, Locally Sourced, All-Natural Snacks and Beverages to Kicks 4 Kids Community ... ... First Soccer and the McHenry Area Soccer Federation have partnered with McHenry’s Healthy U ...
... now new areas in which whole body magnetic resonance imaging ... Deutsches rzteblatt International ( Dtsch Arztebl Int 2010; ... of possible uses, together with the limits of this radiation-free ... routine use in hospitals, as the procedure takes less than ...
... is a great deal of interest in factors that contribute ... One factor that appears to contribute to the heritable ... codes for the serotonin transporter, also known as the serotonin ... transporter gene appears to increase one,s risk for depression and ...
... role of N-terminal pro-B-type natriuretic peptide (NT-proBNP, a protein ... a robust, non-invasive predictor of cardiovascular (CV) risk in ... by the results of a multinational study presented today ... League Against Rheumatism in Rome, Italy. The presence ...
... Grant to ... Athletes , ... June 17, 2010 -- Athletes for Hope (AFH), an entrepreneurial non-profit founded by 12 of ... purpose of inspiring all athletes to engage in positive social impact, has been awarded a ...
Cached Medicine News:Health News:New Web Site Provides Helpful Exercise and Nutrition Tips 2Health News:Healthy U Chosen as Exclusive Concessions Provider for McHenry's 1st Annual Kicks 4 Kids Youth Charity Soccer Tournament, 2Health News:Healthy U Chosen as Exclusive Concessions Provider for McHenry's 1st Annual Kicks 4 Kids Youth Charity Soccer Tournament, 3Health News:Healthy U Chosen as Exclusive Concessions Provider for McHenry's 1st Annual Kicks 4 Kids Youth Charity Soccer Tournament, 4Health News:PTSD: The serotonin system influences vulnerability and treatment 2Health News:NT-proBNP is a predictor of CV risk in arthritis patients taking NSAIDs 2Health News:Athletes for Hope Awarded $2 Million Grant by Kellogg Foundation 2Health News:Athletes for Hope Awarded $2 Million Grant by Kellogg Foundation 3
Indications For Usage: ,Bypass upper airway obstructions, provide long term ventilation, support and/or manage tracheal/bronchial secretions...
Disposable Cannula Cuffless Tracheostomy Tubes...
Indications For Usage: ,For use with percutaneous tracheotomies...
Disposable Cannula Cuffed Tracheostomy Tubes...
Medicine Products: